An Open Label Extension of a Study Comparing Topiramate and Amitriptyline in Migraine Prevention.
CompletedPhase 3NCT00210860
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to assess the long-term safety and effectiveness of topiramate for the prevention of migraine headaches in adults. Topiramate has been approved to prevent migraine headaches in adults.
Study details
- Official title
- An Open-label Study of the Safety and Efficacy of Topiramate for Migraine Prophylaxis: Extension Study to CAPSS-277
- Conditions
- Interventions
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Collaborators
- Ortho-McNeil Neurologics, Inc.
- Start date
- 2004-09
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Diagnosis of migraine with or without aura * Successfully finished CAPSS-277 study * In generally good health * Able to take medicine orally * If female, using birth control Exclusion Criteria: * Not having a more painful condition than the headache pain * Cannot be taking any other medications not allowed by the study * Abnormal liver tests * Not compliant with study medication during the CAPSS-277 study * Pregnant or breast-feeding
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00210860